Condition

Mixed Phenotype Acute Leukemia clinical trials and research

• 21Clinical trials
• 28Countries

Newest Mixed Phenotype Acute Leukemia clinical trials

All recruiting trials (21)

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

• Donor-derived NK-cell infusions to prevent leukemia relapse after stem cell transplant

  This trial tests donor-derived, mbIL21-expanded natural killer (NK) cell infusions given before and after matched-related or haploidentical stem cell transplants to try to prevent relapse in children and young adults (about 1–25 years) with chemorefractory or MRD-positive acute leukemia.

  Recruiting Phase 2 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT07256210

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Decitabine plus FLAG‑Ida chemotherapy and total‑body irradiation before donor stem cell transplant for adults with high‑risk myeloid cancers

  This test tries whether adding decitabine to FLAG‑Ida chemotherapy and total‑body irradiation before a donor stem cell transplant helps adults with high‑risk or relapsed myeloid blood cancers live longer and stay in remission.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06928662

• Orca-T with myeloablative allogeneic stem cell transplant for advanced leukemias and MDS

  This Phase I study tests whether giving Orca-T alongside standard dual‑agent graft‑versus‑host disease prevention is safe in adults (18–70) receiving a myeloablative allogeneic stem cell transplant for acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06551584

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Improving treatment responses in children with T-cell leukemia or lymphoma

  This study is testing if adding two new drugs to standard chemotherapy can help children and young adults with T-cell leukemia or lymphoma have better treatment outcomes.

  Recruiting at 4 sites Phase 2 St. Jude Children's Research Hospital · San Diego, California and 3 other locations · NCT06390319

• Identifying treatment needs for newly diagnosed acute leukemia and lymphoma

  This study is testing a new 7-day chemotherapy treatment for people newly diagnosed with acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia to see how well it works and to better understand their risk of recurrence.

  Recruiting at 5 sites Phase 4 St. Jude Children's Research Hospital · San Diego, California and 4 other locations · NCT06289673

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers

  This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 15 sites Phase 1 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 30 other locations · NCT05476770

• Treatment for infants with specific types of leukemia

  This study is testing a new treatment using blinatumomab for infants with specific types of leukemia to see if it can help them respond better to therapy.

  Recruiting at 101 sites Phase 3 Princess Maxima Center for Pediatric Oncology · Buenos Aires and 123 other locations · NCT05327894

• Engineered donor graft for pediatric blood cancer treatment

  This study is testing a new type of donor graft called Orca-Q to see if it can help children with blood cancers do better after a stem cell transplant.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida and 3 other locations · NCT05322850

• Testing MRX-2843 in adolescents and adults with certain types of leukemia

  This study is testing a new drug called MRX-2843 to see if it is safe and effective for adolescents and adults with certain types of leukemia that have not responded to other treatments.

  Recruiting at 3 sites Phase 1 Meryx, Inc. · Atlanta, Georgia and 2 other locations · NCT04872478

• Combining venetoclax with chemotherapy for treating acute myeloid leukemia

  This study is testing if combining a drug called venetoclax with a specific chemotherapy can help people with acute myeloid leukemia and high-grade myeloid neoplasms feel better and fight their cancer more effectively.

  Recruiting Phase 1/2 University of Washington · Seattle, Washington · NCT04797767

• Screening for pediatric leukemia in children with relapsed or difficult-to-treat cases

  This study is testing how to better screen children and young adults with tough cases of leukemia to see if they qualify for new treatment options.

  Recruiting at 174 sites Phase 1/2 PedAL BCU, LLC · Birmingham, Alabama and 183 other locations · NCT04726241

• Donor stem cell transplant with chemotherapy and radiation for blood cancers

  This study is testing if a donor stem cell transplant combined with different doses of chemotherapy and radiation can help people with blood cancers recover better.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04195633

• Revumenib treatment for relapsed/refractory leukemias with specific genetic mutations

  This study is testing a new drug called revumenib to see if it can help people with certain types of relapsed or hard-to-treat leukemias that have specific genetic changes.

  Recruiting at 38 sites Phase 1/2 Syndax Pharmaceuticals · Duarte, California and 56 other locations · NCT04065399

• Using inotuzumab ozogamicin with chemotherapy for high-risk B-cell leukemia

  This study is testing if adding a targeted therapy called inotuzumab ozogamicin to standard chemotherapy can help young patients with high-risk B-cell leukemia live longer without their cancer coming back.

  Recruiting at 212 sites Phase 3 Children's Oncology Group · Birmingham, Alabama and 230 other locations · NCT03959085

• Evaluating Orca-Q in patients receiving stem cell transplants for blood cancers

  This study is testing a new type of donor graft called OrcaGraft to see if it can make stem cell transplants safer and more effective for people with blood cancers like leukemia.

  Recruiting at 9 sites Phase 1 Orca Biosystems, Inc. · Duarte, California and 11 other locations · NCT03802695

• HA-1 TCR T cell therapy for leukemia that returned or didn't respond after a donor stem cell transplant

  This Phase 1 study will test whether giving specially engineered donor T cells called HA-1 TCR T cells is safe and what dose works for people whose acute leukemia came back or didn't respond after a donor stem cell transplant.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03326921

• Using radioactive treatment before stem cell transplant for high-risk leukemia patients

  This study is testing a new radioactive treatment given before a stem cell transplant to see if it can help high-risk leukemia patients by targeting cancer cells while protecting healthy ones.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03128034

Related topics

Quick answers

How many Mixed Phenotype Acute Leukemia clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 28 countries. The most sites are in United States (19 trials), Australia (5 trials), Canada (3 trials), New Zealand (3 trials), Puerto Rico (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 8, Phase 1: 5, Phase 2: 5, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →